CD74 interacts with APP and suppresses the production of Aβ by unknown
BioMed CentralMolecular Neurodegeneration
ssOpen AcceResearch article
CD74 interacts with APP and suppresses the production of Aβ
Shuji Matsuda, Yukiko Matsuda and Luciano D'Adamio*
Address: Albert Einstein College of Medicine, Department of Microbiology & Immunology, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Email: Shuji Matsuda - smatsuda@aecom.yu.edu; Yukiko Matsuda - ymatsuda@aecom.yu.edu; Luciano D'Adamio* - ldadamio@aecom.yu.edu
* Corresponding author    
Abstract
Background: Alzheimer disease (AD) is characterized by senile plaques, which are mainly
composed of β amyloid (Aβ) peptides. Aβ is cleaved off from amyloid precursor protein (APP) with
consecutive proteolytic processing by β-secretase and γ-secretase.
Results: Here, we show that CD74, the invariant chain of class II major histocompatibility
complex, interacts with APP and serves as a negative regulator of Aβ. CD74 resembles other APP
interacters such as BRI2 and BRI3, since all of them reduce the level of Aβ. However, unlike BRIs,
CD74 does not reduce the secretion of sAPPα or sAPPβ. Interestingly, in HeLa cells, over
expression of CD74 steers APP, but not Notch, to large vacuoles created by CD74.
Conclusion: Taken together, we propose that CD74 inhibits Aβ production by interacting with
and derailing normal trafficking of APP.
Introduction
About 1% of humans aged 60-64 years have AD, increas-
ing steadily to as many as 35%-40% after age 85 [1]. AD
progressively leads to a severely impaired state and com-
plete social dependence. At autopsy, cerebral atrophy,
neurofibrillary tangles and amyloid plaques are observed
in the hippocampus, entorhinal cortex, amygdala and
other areas. Tangles consist of intraneuronal masses of
helically wound filaments of the hyperphosphorylated
protein, tau. Plaques are extracellular deposits of Aβ, a
peptide derived from cleavage of APP, surrounded by dys-
trophic neurites. Most AD cases present Aβ deposits in
cortical and/or meningeal micro vessels. In a minority of
cases, this vascular cerebral amyloid angiopathy (CAA) is
rather severe [2].
APP is a type I transmembrane protein that undergoes a
series of proteolytic cleavages [3]. β-secretase cleaves APP
into a soluble ectodomain (sAPPβ) and a membrane
bound C-terminal fragment of 99 amino acids (C99). C99
is cleaved by the γ-secretase, which consists of a multicom-
ponent complex comprised of Presenilins (PS1 and PS2),
Nicastrin (NCT), PEN2 and APH1 [4]. The γ-cleavage
releases two peptides: Aβ peptide, consisting of 2 major
species of 40 and 42 amino acids (Aβ40 and Aβ42, respec-
tively) and an intracellular product AID/AICD, Several
evidence point to the short AID/AICD as a biologically
active intracellular peptide, which may modulate cell
death, Notch signaling, gene transcription and Ca++
homeostasis [5-19]. In an alternative pathway, APP is
processed by α-secretase within the Aβ sequence, leading
to the production of the soluble sAPPα ectodomain and a
membrane bound C-terminal fragment of 83 amino acids
(C83). After age, a family history of dementia is major risk
factor for AD and 10%-15%, of all AD subjects have a fam-
ily history consistent with an autosomal dominant trait.
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and in Presenilins because they alter the rate of APP
processing and Aβ42 generation.
Given the role of APP processing by secretases to AD
pathology and APP-mediated functions, identifying the
molecules that regulate APP cleavage is physiologically
relevant and of therapeutic interest. A genetic screen
aimed to the identification of regulators of APP processing
led to the identification of BRI2 and BRI3 as APP ligands
that inhibit Aβ formation [20-22]. In the same screening,
we found CD74 as an APP-interacting protein as well.
Human CD74 is a type II transmembrane protein of 216
amino acids which functions as a molecular chaperone of
class II major histocompatibility complex (MIIC) [23],
and at the same time as a receptor for macrophage migra-
tion inhibitory factor (MIF), alone [24] or together with
CD44 [25]. However, little is known about the relation-
ship between CD74 and APP. Because both BRI2 and
BRI3 interact with APP and inhibits APP processing [20-
22,26], we investigated the role of CD74 in regulating the
processing of APP. Here, we show that CD74 interacts
with APP, inhibits Aβ production, and accumulates APP
to endocytotic vacuoles produced by CD74.
Materials and methods
Split-ubiquitin screening
The construction of APP as bait, and screening method
was described elsewhere [20].
Cell culture, transfection, plasmids, antibodies and 
Western blotting
Cell lines, transfection methods, mammalian expression
constructs of APP, APP-Ncas, APP Swedish, APP London,
APP-YFP, myc-tagged Notch, APLP2 were described
[20,27]. CD74 is cloned from the two-hybrid screening,
and its mouse counterparts, Ii p31 and Ii p41 were gener-
ous gifts from Dr. Norbert Koch [28]. All CD74 constructs,
both human and mouse, were cloned into pcDNA3.1 vec-
tor (Invitrogen) with a N-terminal FLAG tag. The Dutch
and Australian mutations of APP were introduced into
APP by QuikChange XL (Stratagene).
The following antibodies and antibody beads were used:
αFLAG (M2, Sigma F1804); αmyc (Cell Signaling, 2276);
αAPP (22C11, Chemicon MAB348); αsAPPα (IBL
11088); αsAPPβ (IBL 18957); αAPP C-terminal fragments
(CTF) (αAPPct, Invitrogen/Zymed 36-6900); αAPLP2
(EMD/Calbiochem 171616); α transferrin receptor; Flag
M2 beads (Sigma A2220). Rabbit polyclonal antibody
and horse radish peroxidase conjugated secondary anti-
bodies are from Southern Biotechnology.
All Western blot samples were separated by 4-12% Crite-
rion Gels (Bio-Rad 3450125) with NuPAGE MES running
buffer (Invitrogen NP0002). The gels were transferred to
nitrocellulose membrane (Whatman BA85 Protran) with
NuPAGE transfer buffer (Invitrogen NP0006) in a Trans-
Blot cell (Bio-Rad). After the transfer, the membrane was
blocked in PBS containing 5% skim milk, and incubated
with indicated primary antibodies over night in the same
buffer. The membrane was washed in PBS containing
0.05% Tween-20, and incubated in corresponding sec-
ondary antibodies for 1 hour. The membrane was washed
in PBS containing 0.05% Tween-20 again, and the bands
were visualized with Super Signal West Pico Chemilumi-
nescent Substrate (Pierce) and Hyblot X-ray films (Den-
ville Scientific).
Immunoprecipitation from HeLa cells
HeLa cells were transfected with indicated combinations
of plasmids. The transfected cells were lysed in the Hepes-
Triton buffer (20 mM Hepes/NaOH pH 7.4, 1 mM EDTA,
150 mM NaCl, 0.5% Triton-X 100) on ice. The lysates
were cleared by spinning at 20,000 g for 10 min. To pre-
cipitate the immune complex, the cleared lysates were
mixed with FLAG beads, or with indicated antibodies and
protein A beads (Pierce). A rabbit polyclonal antibody
was used as a negative control of αAPPct precipitation.
After being washed three times with the same buffer, the
precipitated beads were boiled in 2 × SDS Buffer and ana-
lyzed by Westerm blot. The immunoprecipitants analyzed
correspond to the four times of the inputs.
Staining of transfected HeLa cells
HeLa cells were plated on coverslips coated with poly L-
lysine (Sigma), and were transfected with indicated plas-
mids. The cells on coverslips were fixed, permeabilized
with 0.2% Triton X-100, stained as described [29]. APP-
YFP and Notch-GFP were detected with YFP/GFP fluores-
cence. Anti-FLAG and αAPPct stainings were visualized
with Alexa Fluor 594 goat anti-mouse IgG (H+L) (Invitro-
gen) and Alexa Fluor 488 goat anti-rabbit IgG (H+L) (Inv-
itrogen), respectively. Cells were imaged sequentially with
the Albert Einstein Analytical Imaging Facility BioRad
Radiance 2000 confocal microscope using a 63× NA1.4
oil objective and 488 nm and 568 nm laser lines. The
images shown are representative of the phenotypes
observed in at least three independent experiments.
Colocalization analysis
Regions of interest were analyzed with ImageJ software
(National Institute of Health) and Colocalization Indices
plug-in [30]. Colocalization coefficient (CC) [31] and
intensity correlation quotient (ICQ) [32] were calculated
with the software by setting the threshold of CD74 stain-
ing so that the calculation is limited to CD74-positive vac-
uoles. CC ranges from -1 to 1: 1 indicates completePage 2 of 10
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negative colocalization. Positive ICQ indicates positive
colocalizatioin.
The measurement of APP fragments of HEK293APP cells
HEK293APP cells were transfected with pcDNA3 or with
FLAG-CD74. One day after the transfection, the cells were
further incubated in fresh media for 24 hours. The condi-
tioned media were collected and cleared by spinning at
20,000 g for 10 min. Cells were lysed in the Hepes-Triton
buffer, and protein concentration was determined by
Bradford method using bovine serum albumin as a stand-
ard. Aβ in the media and the cell lysates were measured
using the ELISA kits for Aβ40 and Aβ42 (IBL 17713 and
17711, respectively).
Equal amounts of total lysates and the cleared media were
analyzed by Westerm blot.
The measurement of stability of synthetic Aβ added to the 
media
Synthetic Aβ40 and Aβ42 (American Peptide Company)
were dissolved in 50 mM Tris/HCl pH 8.0 at 1 mg/ml and
stored at -70°C until use. HeLa cells were transfected with
pcDNA3 or FLAG-CD74. One day after transfection, the
media was replaced with fresh media containing synthetic
Aβ40 and Aβ42 at approximately 100 ng/ml. The media
were collected at indicated time points and Aβ was meas-
ured as above.
Metabolic labelling of HeLa cells
HeLa cells were transfected with pcDNA3 or FLAG-CD74
together with APP. One day after the transfection, the cells
were starved for 90 minutes by incubating in DMEM with-
out cysteine and methionine (Invitrogen). The cells were
labelled at 500 Ci/ml of 35S cysteine and methionine for
30 minutes and chased in the complete DMEM for indi-
cated times. After the chase, the cells were lysed and
immunoprecipitated with αAPPct as above. The precipi-
tants were analyzed by SDS-PAGE and autoradiography.
Results
CD74 binds APP
To identify APP ligands, we screened human brain cDNA
library with split-ubiquitin system using APP as bait [20].
This screening is designed so that the each bait and prey
are fused to each half of modified ubiquitin, which upon
interaction releases the DNA binding domain and activa-
tion domain. They are translocated to the nuclei and tran-
scriptionally activate the downstream reporter gene [33].
This screening enabled us to clone transmembrane pro-
teins, which are very difficult to clone in regular yeast two
hybrid screening because the transmembrane proteins do
not translocate to the nucleus to activate the downstream
signal.
One of the clones isolated contained the entire CD74
cDNA (Figure 1A). CD74 serves as an invariant chain of
Class II major histocompatibility complex (MIIC) [34],
and it also serves as a receptor for macrophage migration
inhibitory factor [24]. CD74 is a type II transmembrane
protein, which is processed by protease during its matura-
tion as a chaperon of Class II MHC molecules [23].
In the same split-ubiquitin yeast screening using APP as
bait, we cloned BRI2 and BRI3 [20-22]. Since BRI2 and
BRI3 are also single pass, type II transmembrane proteins
themselves, and interact with APP and inhibit the produc-
tion of Aβ [20-22] we decided to test if the same is true for
CD74 in mammalian cell context.
Full length CD74 with an N-terminal FLAG tag were trans-
fected to HeLa cells. As shown in Figure 1B, the immuno-
precipitation of CD74 from the total lysates indicated that
predominantly mature APP (mAPP) interacted with
CD74. There is little binding to the two APP C-terminal
fragments (APP CTFs, indicated as C99 and C83). No con-
sistent change was observed for the amount of APP CTFs.
This CD74-APP interaction was further confirmed by the
reciprocal immunoprecipitation. The total lysates were
prepared from the HeLa cells cotransfected with FLAG-
CD74 and APP, and the CD74 fragments bound to the
precipitated APP were analyzed. The Westerm blot shows
that CD74 indeed bound to APP. Interestingly, the 33 kDa
fragment (CD74 NTF33), but not the 14 kDa fragment
(CD74 NTF14) of CD74 was associated with APP, even
though NTF14 was clearly the major CD74 NTF in the
total lysates (Figure 1B). The preferred binding of NTF33
over NTF14 indicates that NTF 14 is not sufficient for the
CD74-APP interaction, and hints that the trimeric region
of CD74 is required for the interaction.
Next, we attempted to determine the region of CD74
required for this interaction. cDNA obtained in the two-
hybrid screening, full length CD74, two fragments of
CD74, and the two mouse CD74 isoforms (p31 and p41)
were cloned into a FLAG-tagged mammalian expression
vector (Figure 1A), and cotransfected into HeLa cells
together with APP. Immunoprecipitation with FLAG
beads showed that both human and mouse CD74 bound
mature APP. The lack of interaction found in the deletion
construct CD74 (1-115) confirms that the luminal por-
tion containing the trimeric domain is required for the
CD74 binding to APP. The deletion of first 23 amino acids
(CD74 24-216) also disrupted the interaction, hinting to
the possibility that the endosomal-targeting signal [35]
might be involved in this interaction.
CD74 does not interact with Notch or APLP2
To investigate the specificity of CD74-APP binding, myc-
tagged Notch and APLP2 were transfected into HeLa cellsPage 3 of 10
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the transfected cells were precipitated with FLAG beads to
analyze if Notch or APLP2 co purified with CD74. As indi-
cated in Figure 2A, CD74 did not precipitate Notch. Nor
did it precipitate APLP2, a close homolog of APP (Figure
2B). The lack of interaction with Notch or APLP2 further
attests the specificity of the CD74-APP interaction.
CD74 over expression does not change sAPPα and sAPPβ
Next, we tested how other APP metabolites were affected
by the overexpression of CD74. HeLa cells were trans-
fected with APP together with pcDNA3, FLAG-CD74,
FLAG-CD74 (24-216), and mouse CD74 (Ii p31), and
one day later, the cells were further incubated in fresh
media for 24 hours. APP fragments in the media and in
the cell were analyzed by Westerm blot. As shown in Fig-
ure 2C, CD74 over expression did not show significant
change in APP, APP CTFs, sAPPα, or sAPPβ (left panels:
Western blots, right panels: quantification of the blots).
Student's t test showed no significant difference between
any combinations of the values.
CD74 over expression reduces secreted Aβ, but does not 
change the cytoplasmic Aβ40
Next, we asked if CD74 changes the production of Aβ.
HEK293APP cells, which stably express APP, were trans-
fected with pcDNA3 or with FLAG-CD74. The transfect-
ants were further incubated in fresh media as above and
the secreted Aβ40 and Aβ42 were measured with Aβ
ELISA. As shown in Figure 2D, exogenous expression of
CD74 decreased both the secreted Aβ40 and Aβ42. On the
contrary, there is no significant change of cytoplasmic
Aβ40 (Figure 2E). The levels of cytoplasmic Aβ42 were too
low to be detected (data not shown).
CD74 overexpression does not change the stability of Aβ 
added to the media, or the metabolism of cell-bound APP
Next, we questioned if the overexpression of CD74 affects
the stability of Aβ added to the media. HeLa cells were
transfected with pcDNA3 or FLAG-CD74. On the next
day, the media was replaced with fresh media containing
of Aβ40 and Aβ42. The ELISA of the media taken at the
indicated time points showed there was no significant dif-
ference in the stability of Aβ40 (p = 0.890) and Aβ42 (p =
0.141) by paired Student's t test analysis (Figure 2E).
In order to determine whether metabolism of APP is mod-
ified by CD74, we performed pulse-chase labeling of APP.
HeLa cells were transfected with pcDNA3 or FLAG-CD74
together with APP. The cells were pulse labeled with 35S
methionine and cysteine and chased for indicated hours.
The autoradiography of immunoprecipitated APP indi-
cates that CD74 did not change the conversion of cell-
bound APP significantly (Figure 2F).
CD74 interacts with APP-Ncas, and other APP FAD 
mutants
Next, we tested if various mutants of APP interact with
CD74. HeLa cells were transfected with APP, APP-Ncas,
APP Swedish, APP Dutch, APP London, and APP Austral-
ian mutants. These are all APP mutations that in humans
cause familial forms of Alzheimer's disease [36], except
for APP-Ncas that is an APP construct missing the COOH-
terminal 31 amino acids [37]. The lysates were prepared
from the transfected cells, and CD74 was precipitated. The
FLAG immunoprecipitations show that CD74 fully inter-
acts with mature form of all APP variants (Figure 2G).
CD74 changes the intracellular distribution of APP
Next, we sought to identify how CD74 and APP are dis-
tributed inside the cell. As shown in Figure 3A for Hela
cells transfected with APP-YFP or FLAG-CD74, APP is
localized in intracellular reticular structures, while CD74
is targeted to endosomes [35]. Overexpression of CD74
and has been reported to create vacuoles [35] that we also
can appreciate (Figure 3A).
When these two were co expressed in the same cell, a sig-
nificant portion of APP co localized with CD74 in these
vacuoles (Figure 3B, upper panels). This CD74-dependent
redistribution of APP is specific since, for example, CD74
did not co-localize in these vacuolar structures with
A) A cartoon of various FLAG-tagged CD74 constructs: the yeast split-ubiquitin (TH) clone, full length CD74, two deletions construc s f CD74, and two splicing variants f mouse CD74Figure 1 (see previous page)
A) A cartoon of various FLAG-tagged CD74 constructs: the yeast split-ubiquitin (TH) clone, full length CD74, 
two deletions constructs of CD74, and two splicing variants of mouse CD74. The cytoplasmic and luminal parts, the 
locations of the FLAG tag, the endosomal-sorting signal in the cytoplasmic domain (LL), the CLIP domain (C), and the trimeric 
domain (T) are indicated. B) HeLa cells were transfected with pcDNA3 (-) or FLAG-CD74 (+) together with APP, and the total 
cell lysates (TL) and FLAG immunoprecipitants (IP) were analyzed by Westerm blot. Full length APP, APP CTF (C99 and C83), 
and CD74 were detected with 22C11, αAPPct, and αFLAG antibodies, respectively. The 33 and 14 kDa N-terminal fragments 
of CD74 were designated as CD74 NTF33 and NTF14. C) HeLa cells were transfected with FLAG-CD74 and APP, and the 
total lysates of the transfected cells were immunoprecipitated with either rabbit polyclonal antibody (RP) or αAPPct, and ana-
lyzed as in B. D) HeLa cells were transfected with various CD74 constructs and APP. The total lysates and FLAG IPs were ana-
lyzed as in B. Mature APP and immature APP (mAPP/imAPP) are indicated. The bands marked with asterisks (*) were 
attributed to the FLAG antibody used in the immunoprecipitation.Page 5 of 10
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cal observation that CD74 does not bind Notch (Figure
2A).
Next, we tested if the major APP CTF fragments, C99 and
C83, changed intracellular localization if expressed
together with CD74. For this, HeLa cells were cotrans-
fected with these APP variants and FLAG-CD74, and
stained with αAPPct to visualize APP, C99 and C83, and
αFLAG to visualize CD74. As expected, APP co localized
with CD74 nicely in the vacuolar structures. However,
C99 and C83 did not show detectable accumulation to
the CD74 induced vacuolar structures. This observation
could explain the initial immunoprecipitations results
that CD74 barely interact with APP CTFs (Figure 1B).
Discussion
We isolated CD74, together with the familial dementia
gene BRI2 and its family member BRI3, during a genetic
screening for membrane-bound APP ligands [20,21].
CD74 is known to work as a chaperon of class II major
histocompatibility complex in B cells, which present anti-
gens to T cells [34,38]. Interestingly, the functions of
CD74 are not limited to the chaperons in the immune
cells. Recently, CD74 has been proposed to serve as a
receptor for macrophage migration inhibitory factor [24].
CD74 associates with Class II MHC in endoplasmic retic-
ulum. After it is transported through post-Golgi compart-
ments, the complex are diverted to endocytic vesicles, and
CD74 is proteolytically processed to CLIP region (Figure
1A), which remains bound to Class II MHC [23,38]. APP
does not associate CD74 in endoplasmic reticulum, since
only fully glycosylated APP binds to CD74 (Figure 1B),
and CD74 does not change the rate of maturation of APP
(Figure 2F). Thus it is unlikely that CD74 functions as ER
chaperones as in the case of Class II MHC.
We previously showed that the familial dementia gene
BRI2 and its homologue BRI3 are inhibitors of APP
processing [20,21]. Here, we have established that CD74
binds APP and inhibits the production of Aβ. Like the two
members of the BRI gene family, CD74 is also a type II
transmembrane protein, but structurally unrelated to BRIs
(Figure 1A). CD74 can immunoprecipitate APP (Figure
1B). Reciprocal immunoprecipitations shows APP can
precipitate CD74 (Figure 1C). Both N-terminal 23 amino
acids and C-terminal 101 amino acids of CD74 are
required for the interaction (Figure 1D). On the APP side,
C99 and C83 scarcely bind CD74 (Figure 1A).
This binding of CD74 to APP is similar to that of BRI2 or
BRI3, in that only the mature form of APP binds CD74
(Figure 1A). However, there is a clear difference: CD74
does not cause the accumulation of C99 as in the case of
BRI2, nor does it bind to C99 (Figure 1B). Or, contrary to
BRI2 and BRI3, CD74 does not inhibit secretion of sAPPα
or sAPPβ (Figure 2C) [20-22]. Therefore, it is unlikely that
CD74 is working on APP by masking the secretase sites as
in the case of BRI2 and BRI3. Rather, CD74 might be redi-
recting APP to intracellular compartments where the pro-
duction of Aβ in reduced.
As shown in Figure 2D-F, CD74 does reduce the Aβ in the
media when APP is co transfected, but it does not change
the cytoplasmic Aβ40 (Figure 2D), or the stability of exog-
enously added Aβ (Figure 2E), or the maturation of APP
(Figure 2F). These data further support our notion that
CD74 works on APP inside cells after APP is matured, and
not by destabilizing Aβ already secreted in the media.
A) HeLa cells were transfected with pcDNA3 (-) or CD74 (+), together with NotchFigure 2 (see previous page)
A) HeLa cells were transfected with pcDNA3 (-) or CD74 (+), together with Notch. The total cell lysates (TL) and 
FLAG IPs were analyzed as in Figure 1B. Notch was detected with αmyc antibody. B) HeLa cells were transfected with 
pcDNA3 (-) or CD74 (+), together with APLP2, and were analyzed as in A. C) Left panels: HEK293APP cells were transfected 
with the indicated plasmids. The transfected cells were further incubated for 24 hours with fresh media, and secreted sAPPα/β 
were measured by Westerm blot. The cell lysates were analyzed as in Figure 1B. Right panels: the quantification of sAPPα/β. 
The levels in pcDNA3 transfected cells were set to 100. D) HEK293APP cells were transfected with pcDNA3 or CD74 and 
treated as in C. Aβ40 and 42 secreted in the media, and Aβ40 in the lysates were measured with specific ELISA. The amount of 
Aβ was normalized to the amount of the protein in the total lysates. The asterisks (**) indicate that p values by Student's t test 
are less than 0.01. E) HeLa cells were transfected with pcDNA3 or CD74, and the media was replaced with fresh media con-
taining synthetic Aβ40 and Aβ42. The media of pcDNA3 (open circles) and CD74 (closed circles) transfected cells were incu-
bated for indicated hours, and the remaining Aβ40 and Aβ42 were measured as in D. F) HeLa cells were transfected with 
pcDNA3 or FLAG-CD74 together with APP. The cells were pulsed for 30 min with 35S methionine+cysteine, and chased in 
fresh media for indicated hours. APP was immunoprecipitated with αAPPct antibody and analyzed by SDS-PAGE followed by 
autoradiography. G) HeLa cells were transfected with pcDNA3 (-) or FLAG-CD74 (+) together with wild type APP (wt APP) 
or the indicated mutants. The total lysates and FLAG IPs were processed as in Figure 1B. Note that APP Ncas lacks C-terminal 
31 amino acids of APP and has therefore a smaller in size.Page 7 of 10
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A) HeLa cells were transfected with APP-YFP or FLAG-CD74Figure 3
A) HeLa cells were transfected with APP-YFP or FLAG-CD74. APP and CD74 were detected by YFP fluorescence 
and αFLAG antibody staining with Alexa594 anti-mouse secondary antibody, respectively. Corresponding phase contrast views 
were shown. B) HeLa cells were transfected with APP-YFP or Notch-GFP together with FLAG-CD74. Notch was detected by 
GFP fluorescence. APP and CD74 were detected as in A. Digitally merged pictures of Green and Red channels and phase con-
trast view are also displayed. Colocalization Coefficient (CC) and Intensity Correlation Quotient (ICQ) were indicated. C) 
HeLa cells were transfected with APP, C99 or C83 together with FLAG-CD74. APP, C99, and C83 were detected with the 
αAPPct antibody, and FLAG-CD74 was detected as above. Merged pictures and phase contrast views were shown as in B. Bar 
= 10 μm. CC and ICQ are as in B.
Molecular Neurodegeneration 2009, 4:41 http://www.molecularneurodegeneration.com/content/4/1/41It is noteworthy that the major metabolite of CD74
(CD74NTF14) does not interact with APP, but the minor
fragment (NTF33) does (Figure 1C). This observation
strongly argues that the CD74-APP interaction is specific
because APP distinguishes NTF33 from NTF14; and the
interaction occurs before CD74 is irreversibly processed
further than NTF33; and at least NTF33 is required for the
interaction. We cannot conclude that NTF33 is the mini-
mal region required for the CD74-APP interaction
because NTF33 might interact with APP indirectly, in a
trimer with full length CD74. The precise dissection of the
minimal region responsible for the binding requires fur-
ther study, and should take into account the fact that
CD74 forms trimers [34,38].
APP and CD74 displays distinct intracellular distribution.
When transfected independently, APP displays reticular
and vesicular structures in the cytoplasm. In contrast,
CD74 shows larger vacuoles, which are endosomal in
nature [35]. Our observation that APP co localizes with
CD74 in vacuolar structure in HeLa cells (Figure 3B, upper
panels) supports the notion that CD74 and APP interact.
Moreover, the striking APP re-distribution to CD74-posi-
tive vacuolar structures suggests that this change is caused
by the physical interaction of CD74 and APP. Co expres-
sion of CD74 and either Notch, C99 or C83 (all molecules
that do not bind CD74) show the specificity of this phe-
nomenon since Notch, C99 and C83 do not accumulate
in CD74-positive vacuoles upon co expression (Figure 3B,
lower panels, and 3C).
Thus we propose that unlike BRI2 or BRI3, which are
working directly on APP by blocking the access of secre-
tases to APP, CD74 interferes with APP processing by reg-
ulating the sub-cellular localization of APP in
compartments where amyloidogenic APP cleavage is
reduced.
Little is known about the relationship between CD74 and
AD. In immuno-histochemistry experiments, normal
brains do not stain well for CD74 and CD74 is mostly
expressed in microglia. However, the brains of AD
patients have increased CD74 staining [39]. Interestingly,
a recent study shows that CD74 is accumulated in neu-
rons with paired helical fibers [40]. Our findings suggest
that CD74 may be a player in controlling APP biology and
processing, perhaps regulating APP trafficking in neurons.
Given the anti-amyloidogenic activity of CD74, it is possi-
ble that the increased levels of CD74 in AD brains, poten-
tially caused by increased TNFα in AD patients and in
transgenic mouse over expressing APP [41-43], could con-
tribute to a negative feedback mechanism of the organism
to fend off noxious APP processing up regulation.
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